

Supplement Documents for Results FY2009

Astellas Pharma Inc.

- Financial Results of FY2009

Cautionary statement regarding forward-looking information

This material includes forward-looking statements based on a number of assumptions and beliefs in light of the information currently available to management and subject to significant risks and uncertainties. Actual financial results may differ materially depending on a number of factors, including adverse economic conditions, currency exchange rate fluctuations, adverse legislative and regulatory developments, delays in new product launches, the pricing and product initiatives of competitors, the inability of the company to market existing and new product effectively, interruptions in production, infringement of the company's intellectual property rights and the adverse outcome of material litigation.

1. Detailed Information by Operating Results

	rounddown under 0.1 billion yen		billion yen		Mar 10 Revised	Forecasts		Forecasts	
	Mar 09 Full Year	Mar 10 Full Year	Change	Change (%)		Mar 11 2Q	Change (%)	Mar 11 Full Year	Change (%)
Net Sales	965.6	974.8	9.1	1.0%	976.0	457.0	-7.6%	940.0	-3.6%
Cost of Sales	264.4	289.2	24.8	9.4%					
Ratio to Net Sales	27.4%	29.7%							
Gross Profit	701.2	685.6	-15.6	-2.2%					
SG&A	450.8	499.2	48.3	10.7%	179.0	86.0	9.2%	182.0	-6.9%
Ratio to Net Sales	46.7%	51.2%							
Research and Development	159.0	195.5	36.5	23.0%					
SG&A excluding R&D	291.8	303.6	11.8	4.1%					
Advertising and Sales Promotion	84.8	87.7	2.9	3.4%					
Salaries, Bonuses and Allowances	115.1	120.0	4.9	4.3%					
Other	91.8	95.8	3.9	4.3%					
Operating Income	250.3	186.4	-63.9	-25.6%	200.0	80.0	-38.1%	152.0	-18.5%
Ratio to Net Sales	25.9%	19.1%			20.5%	17.5%		16.2%	
Non-Operating Income	22.2	5.1	-17.0	-76.8%					
Exchange Gain	9.2	0.2	-9.0	-97.6%					
Equity in earnings of affiliates	-	0.0	0.0	-					
Non-Operating Expenses	1.1	0.5	-0.5	-50.3%					
Equity in losses of affiliates	0.0	-	-0.0	-					
Ordinary Income	271.4	190.9	-80.4	-29.6%	200.5	81.5	-36.5%	155.0	-18.8%
Ratio to Net Sales	28.1%	19.6%			20.5%	17.8%		16.5%	
Special Gains	1.9	3.0	1.1	59.1%					
Gain on sales of fixed assets	1.3	0.0	-1.2	-96.4%					
Special Losses	10.6	7.2	-3.4	-32.4%					
Loss on sale and disposal of fixed assets	3.0	2.2	-0.7	-25.9%					
Impairment Loss	1.3	4.0	2.7	204.6%					
Loss on devaluation of investments securities	1.9	-	-1.9	-					
Special Retirement Benefits	2.5	-	-2.5	-					
Other	1.7	0.8	-0.8	-51.4%					
Income before Income Taxes	262.6	186.8	-75.8	-28.9%					
Income Taxes	89.6	62.6	-27.0	-30.1%					
Minority Interests	2.0	1.9	-0.1	-6.9%					
Net Income	170.9	122.2	-48.7	-28.5%	125.0	57.0	-31.7%	107.0	-12.5%
Ratio to Net Sales	17.7%	12.5%			12.8%	12.5%		11.4%	

2. Segment Information by Business

		billion yen			
		Mar 09 Full Year	Mar 10 Full Year	Change	Change (%)
Sales	Consolidated	965.6	974.8	9.1	1.0%
	Pharmaceutical	964.6	973.8	9.1	1.0%
	Ratio to Net Sales	99.9%	99.9%		
	Other	1.0	0.9	-0.0	-1.5%
	Ratio to Net Sales	0.1%	0.1%		

Mar 10 Revised
976.0

Forecasts		Forecasts	
Mar 11 2Q	Change (%)	Mar 11 Full Year	Change (%)
457.0	-7.6%	940.0	-3.6%

3. Overseas Sales

		billion yen			
		Mar 09 Full Year	Mar 10 Full Year	Change	Change (%)
Overseas Sales		468.9	460.7	-8.2	-1.8%
	Ratio to Net Sales	48.6%	47.3%		
	North America	235.0	224.8	-10.1	-4.3%
	Ratio to Net Sales	24.3%	23.1%		
	Europe	180.3	181.2	0.8	0.5%
	Ratio to Net Sales	18.7%	18.6%		
	Asia and others	53.5	54.5	1.0	1.9%
	Ratio to Net Sales	5.6%	5.6%		

Mar 10 Revised
436.9
44.8%

Forecasts	
Mar 11 Full Year	Change (%)
410.5	-10.9%
43.7%	

- Calculated according to locations of buyers.

4. Segment Information by Region

		billion yen			
		Mar 09 Full Year	Mar 10 Full Year	Change	Change (%)
Sales		965.6	974.8	9.1	1.0%
Japan		510.4	529.2	18.7	3.7%
	Ratio to Net Sales	52.9%	54.3%		
North America		188.8	179.8	-9.0	-4.8%
	Ratio to Net Sales	19.6%	18.4%		
Europe		239.1	235.8	-3.2	-1.4%
	Ratio to Net Sales	24.8%	24.2%		
Asia		27.2	29.9	2.7	10.0%
	Ratio to Net Sales	2.8%	3.1%		
Operating Income		250.3	186.4	-63.9	-25.6%
Japan		175.5	114.5	-61.0	-34.8%
	Ratio to Net Sales	70.1%	61.4%		
North America		32.8	14.8	-18.0	-54.9%
	Ratio to Net Sales	13.1%	7.9%		
Europe		39.8	43.9	4.1	10.3%
	Ratio to Net Sales	15.9%	23.6%		
Asia		3.3	2.3	-1.0	-31.7%
	Ratio to Net Sales	1.3%	1.2%		
Eliminations		-1.2	10.8	12.0	

- Calculated according to locations of sellers.

Mar 10 Revised
976.0
539.1
55.2%
179.6
18.4%
228.0
23.4%
29.3
3.0%
200.0

Forecasts		Forecasts	
Mar 11 2Q	Change (%)	Mar 11 Full Year	Change (%)
457.0	-7.6%	940.0	-3.6%
257.0	-0.3%	527.2	-0.4%
56.2%		56.1%	
81.9	-18.0%	174.6	-2.9%
17.9%		18.6%	
100.6	-17.2%	202.8	-14.0%
22.0%		21.6%	
17.5	13.5%	35.4	18.1%
3.8%		3.8%	
80.0	-38.1%	152.0	-18.5%

5.Exchange Rate

	yen			
	Mar 09 Ave	Mar 10 Ave	Mar 09 End	Mar 10 End
Yen/USD	101	93	98	93
Yen/EUR	143	131	130	125

Mar 10 Revised
93
132

Forecasts	
Mar 11 2Q	Mar 11 Full Year
90	90
130	130

Forecasts	
Mar 11 2Q	Mar 11 Full Year
90	90
130	130

*Exchange rate fluctuations had negative impacts by 39.3 billion yen on net sales and by 17.2 billion yen on operating income in FY09.

6.Per Share Information

	Mar 09 Full Year	Mar 10 Full Year
The number of share issued (thousand)	503,964	475,964
Treasury Stock (thousand)	33,948	14,146
The number of share issued after deducting Treasury Stock	470,016	461,817
Earnings per share (Yen)	356.11	261.84
Dividend per share (Yen)	120	125
Return on Equity (%)	16.0%	11.7%
Dividend on Earnings (%)	5.4%	5.6%

Mar 10 Revised
265.95
125

Forecasts	
Mar 11 2Q	Mar 11 Full Year
123.43	231.69
60	125

Forecasts	
Mar 11 2Q	Mar 11 Full Year
123.43	231.69
60	125

7.Research and Development Expenses

	billion yen			
	Mar 09 Full Year	Mar 10 Full Year	Change	Change (%)
Research and Development expenses	159.0	195.5	36.5	23.0%
Ratio to Net Sales	16.5%	20.1%		

billion yen	
Mar 10 Revised	Mar 10 Full Year
179.0	18.3%
18.3%	

Forecasts		Forecasts	
Mar 11 2Q	Change (%)	Mar 11 Full Year	Change (%)
86.0	9.2%	182.0	-6.9%
18.8%		19.4%	

8.Addition to Property, Plant and Equipment

	billion yen			
	Mar 09 Full Year	Mar 10 Full Year	Change	Change (%)
Addition to Property, Plant and Equipment				
Consolidated	37.6	37.7	0.1	0.4%
Depreciation(Tangible)				
Consolidated	24.7	28.0	3.2	13.2%
Depreciation(Intangible)				
Consolidated	10.6	10.6	-0.0	-0.3%
Amortization of Goodwill	7.4	9.7		

billion yen	
Mar 10 Revised	Mar 10 Full Year
36.2	
27.1	
10.0	
8.8	

Forecasts	
Mar 11 Full Year	Change (%)
41.0	8.5%
28.0	-2.1%
12.0	12.1%
7.3	

9. Employee

Number of employees

	Mar 09 Full Year	Mar 10 Full Year
Total	14,261	15,161
Japan	7,522	7,860
North America	2,318	2,375
Europe	3,390	3,775
Asia	1,031	1,151
Total Medical Representatives	5,150	5,500

10. Shareholders

	Mar 09 Full Year	Mar 10 Full Year
Banks	36.2%	33.7%
Securities	1.8%	4.2%
Other companies	3.9%	4.0%
Foreign companies	43.2%	46.3%
Individuals and others	8.2%	8.8%
Treasury Stock	6.7%	3.0%

11.Detailed Pharmaceutical Segment Information

1)Consolidated sales of major products

	billion yen			
	Mar 09 Full Year	Mar 10 Full Year	Change	Change (%)
Prograf	201.0	186.7	-14.3	-7.1%
Sales by Astellas	194.7	180.5	-14.1	-7.3%
Japan	28.5	33.8	5.2	18.4%
North America	88.8	68.1	-20.6	-23.3%
Europe	66.0	65.7	-0.3	-0.5%
Advagraf	6.3	12.1	5.7	90.3%
Asia	11.2	12.8	1.5	13.8%
Exports to third parties(Europe)	6.3	6.2	-0.1	-1.8%
Harnal	116.6	113.9	-2.7	-2.4%
Sales by Astellas	70.0	68.2	-1.8	-2.6%
Japan	35.6	35.0	-0.6	-1.7%
Europe	25.7	24.3	-1.4	-5.6%
Capsule	9.2	8.1	-1.1	-12.4%
Omniv OCAS	16.5	16.2	-0.2	-1.8%
Asia	8.1	8.6	0.4	5.0%
Bulk and Royalties(Europe)	46.6	45.6	-0.9	-2.1%
Vesicare	71.4	82.3	10.9	15.3%
Japan	19.0	22.9	3.9	20.7%
North America	31.0	35.1	4.1	13.2%
Europe	20.6	22.9	2.3	11.4%
Asia	0.7	1.0	0.3	48.7%
Funguard/Mycamine	17.5	21.6	4.1	23.6%
Japan	11.6	11.8	0.1	1.3%
North America	5.1	7.5	2.4	47.7%
Europe	0.1	1.2	1.1	934.4%
Asia	0.5	1.0	0.4	79.4%
Protopic	16.1	16.4	0.3	1.9%
Japan	2.7	2.8	0.1	5.8%
North America	7.6	7.3	-0.3	-4.1%
Europe	5.2	5.5	0.2	5.1%
Asia	0.5	0.7	0.1	35.9%

- Sales of products in Japan are shown in a gross sales basis.

	billion yen		Forecasts		Forecasts	
	Mar 10 Revised	Change (%)	Mar 11 2Q	Change (%)	Mar 11 Full Year	Change (%)
	184.3		81.8	-20.7%	163.6	-12.4%
	178.5		79.2	-20.9%	158.5	-12.2%
	34.7		18.8	14.1%	38.8	14.8%
	66.6		21.3	-51.0%	43.1	-36.8%
	64.3		32.0	-4.1%	62.1	-5.5%
	12.8		7.1	5.0%	14.5	13.0%
	5.7		2.6	-14.4%	5.0	-19.1%
	106.7		34.0	-45.6%	67.3	-41.0%
	68.5		31.9	-7.9%	63.0	-7.7%
	35.7		15.5	-13.2%	30.3	-13.6%
	24.2		11.3	-8.0%	22.4	-8.0%
	7.1		3.4	-11.9%	6.9	-15.4%
	17.1		7.9	-6.2%	15.5	-4.3%
	8.3		4.6	4.5%	9.2	7.4%
	38.2		2.2	-92.3%	4.3	-90.7%
	82.8		46.8	16.6%	98.3	19.3%
	22.9		12.7	19.3%	26.5	15.4%
	35.6		19.6	11.2%	42.1	19.6%
	23.2		13.7	22.0%	28.1	22.2%
	1.1		0.7	53.2%	1.7	54.6%
	20.5		12.1	16.6%	24.9	15.2%
	11.7		6.0	0.1%	11.7	-1.0%
	6.7		3.9	11.0%	8.4	10.3%
	1.2		1.2	242.2%	3.0	140.7%
	0.9		0.9	97.2%	1.9	81.5%
	16.6		9.5	13.8%	19.3	17.0%
	2.9		1.5	3.1%	2.9	0.9%
	7.4		4.2	11.2%	8.6	18.3%
	5.5		3.1	18.3%	6.4	15.0%
	0.9		0.6	44.8%	1.4	81.0%

2) Consolidated Sales of Other Products

Rx Sales in Japan <Global products>	billion yen			
	Mar 09 Full Year	Mar 10 Full Year	Change	Change (%)
Prograf (Including Gracepter)	28.5	33.8	5.2	18.4%
Harnal	35.6	35.0	-0.6	-1.7%
Vesicare	19.0	22.9	3.9	20.7%
Funguard	11.6	11.8	0.1	1.3%
Protopic	2.7	2.8	0.1	5.8%

<Domestic Products>

Lipitor	95.3	99.9	4.6	4.8%
Micardis	64.4	71.6	7.2	11.2%
Micombi(Launched in June 2009)	-	1.6	1.6	-
Gaster	53.0	49.9	-3.1	-5.9%
Myslee	25.7	29.1	3.3	13.2%
Seroquel	21.0	23.6	2.5	12.2%
Vaccines	17.3	25.2	7.9	45.6%
Cefzon	11.7	10.6	-1.1	-9.6%
Frاندol	11.3	11.0	-0.3	-2.7%
Luvox	10.0	9.4	-0.6	-6.3%
Celecox	10.4	17.8	7.3	70.2%
Geninax	6.4	8.1	1.6	26.1%
Irribow	1.6	0.2	-1.4	-87.1%
Bonoteo (Launched in April 2009)	-	1.0	1.0	-
Symbicort (Launched in January 2010)	-	1.5	1.5	-
Total Rx Sales In Japan	491.5	509.8	18.2	3.7%

- Sales of products in Japan are shown in a gross sales basis.

billion yen
Mar 10 Revised
34.7
35.7
22.9
11.7
2.9

98.8
72.4
50.5
28.6
23.4
33.1
10.8
11.1
9.8
17.0
9.0
0.6
1.3
-
523.2

Forecasts		Forecasts	
Mar 11 2Q	Change (%)	Mar 11 Full Year	Change (%)
18.8	14.1%	38.8	14.8%
15.5	-13.2%	30.3	-13.6%
12.7	19.3%	26.5	15.4%
6.0	0.1%	11.7	-1.0%
1.5	3.1%	2.9	0.9%
47.7	-3.4%	92.4	-7.5%
36.1	0.9%	72.7	1.4%
21.3	-16.6%	41.4	-17.1%
15.9	13.2%	32.0	9.7%
12.8	10.8%	25.8	9.1%
4.1	-20.1%	18.1	-28.4%
4.5	-17.3%	9.2	-13.6%
5.1	-9.4%	10.0	-9.4%
4.4	-10.2%	8.3	-12.1%
12.2	56.2%	26.6	49.2%
3.7	16.5%	9.4	15.5%
0.9	508.7%	1.9	775.2%
0.8	-3.2%	1.6	46.9%
1.9	-	7.1	366.9%
250.0	1.3%	510.9	0.2%

RX Sales in North America and Europe		billion yen			
		Mar 09 Full Year	Mar 10 Full Year	Change	Change (%)
Scan*	(North America)	39.3	46.0	6.7	17.2%
	Lexiscan	9.4	30.2	20.8	221.1%
	AmBisome (North America)	6.1	6.2	0.0	0.8%
	Vaprisol (North America)	0.7	1.0	0.2	37.7%
	Amevive (North America)	1.7	1.2	-0.4	-27.0%
	VIBATIV (Launched in November 2009) (North America)	-	0.3	0.3	-
	Eligard (Europe)	12.5	14.1	1.6	13.0%

* Adenoscan + Lexiscan

Export Sales		billion yen			
		Mar 09 Full Year	Mar 10 Full Year	Change	Change (%)
Cefzon	Overseas (Exports to third parties)	1.1	1.1	-0.0	-7.8%
Cefspan	Overseas (Exports to third parties)	6.0	6.3	0.3	5.7%

billion yen
Mar 10 Revised
46.6
5.9
1.3
1.8
-
14.1

billion yen
Mar 10 Revised
1.0
5.5

Forecasts		Forecasts	
Mar 11 2Q	Change (%)	Mar 11 Full Year	Change (%)
24.2	3.6%	50.7	10.1%
3.0	-3.5%	6.0	-3.2%
0.7	13.2%	1.4	33.6%
0.6	-12.5%	1.2	-5.2%
-	-	-	-
7.4	10.3%	15.2	7.2%

Forecasts		Forecasts	
Mar 11 2Q	Change (%)	Mar 11 Full Year	Change (%)
0.7	19.1%	1.3	16.6%
2.6	-30.1%	5.7	-11.1%

Sales in North America and Europe

North America	Unit:M\$			
	Mar 09 Full Year	Mar 10 Full Year	Change	Change (%)
Sales	1,878	1,936	58	3.1%
Prograf	884	734	-149	-16.9%
Scan*	390	495	105	26.9%
Lexiscan	93	326	232	247.7%
Ambisome	61	67	5	9.2%
Protopic	75	78	2	3.9%
VESIcare	308	378	69	22.6%
Mycamine	51	81	30	59.9%
Vaprisol	7	10	3	49.1%
Amevive	16	13	-3	-20.9%
VIBATIV (Launched in November 2009)	-	4	4	-

* Adenoscan + Lexiscan

Unit:M\$
Mar 10 Revised
1,937
719
502
64
80
384
72
14
19
-

Forecasts		Forecasts	
Mar 11 2Q	Change (%)	Mar 11 Full Year	Change (%)
910	-13.0%	1,941	0.2%
237	-48.0%	479	-34.8%
268	9.9%	563	13.6%
33	2.4%	67	-0.1%
47	17.9%	96	22.0%
218	18.0%	467	23.4%
44	17.7%	93	13.8%
7	20.1%	15	37.8%
7	-7.2%	13	-2.2%
-	-	-	-

Europe	Unit:ME			
	Mar 09 Full Year	Mar 10 Full Year	Change	Change (%)
Sales	1,666	1,798	131	7.9%
Harnal	504	533	29	5.8%
Sales by Astellas	179	185	5	3.3%
Capsule	64	61	-3	-4.2%
OCAS	115	123	8	7.5%
Bulk and Royalties	324	348	23	7.2%
Prograf	502	545	43	8.6%
Sales by Astellas	460	501	40	8.9%
Advagraf	44	92	48	108.2%
Exports to third parties	42	44	2	5.6%
Vesicare	143	175	31	21.9%
Protopic	36	42	5	15.0%
Mycamine	0	9	8	1031.7%
Eligard	87	107	20	23.7%

Unit:ME
Mar 10 Revised
1,733
474
184
54
130
290
532
489
43
176
42
9
108

Forecasts		Forecasts	
Mar 11 2Q	Change (%)	Mar 11 Full Year	Change (%)
774	-15.2%	1,560	-13.3%
103	-65.8%	205	-61.6%
87	-5.8%	172	-7.2%
26	-9.8%	53	-14.7%
61	-3.9%	119	-3.5%
17	-92.1%	33	-90.6%
265	-2.3%	516	-5.5%
246	-1.7%	478	-4.6%
20	-8.8%	38	-14.9%
105	25.0%	216	23.3%
24	21.2%	49	16.0%
10	250.5%	23	142.9%
57	13.0%	117	8.1%

12.Consolidated Balance Sheets

				Billion yen	
		31-Mar-10	31-Mar-09	Change	Comments
		Amount	Amount		
Assets		1,364.1	1,348.4	15.7	
Current assets		988.5	963.6	24.9	
	Cash on hand and in banks	312.1	267.4	44.7	Cash on hand and in banks / Marketable securities } (+23.3)
	Trade notes and accounts receivable	228.0	222.9	5.1	
	Marketable securities	225.0	246.4	-21.3	
	Merchandise and finished goods	82.7	80.7	1.9	
	Work in process	12.1	12.5	-0.3	
	Raw materials and supplies	16.1	12.1	3.9	
	Deferred tax assets	63.3	67.5	-4.2	
	Other	50.4	54.7	-4.2	
	Allowance for doubtful receivables	-1.6	-1.0	-0.6	
Fixed assets		375.6	384.8	-9.1	
Property, plant and equipment		184.4	181.4	3.0	
	Buildings and structures	96.1	96.1	-0.0	
	Machinery, equipment and vehicles	22.3	23.6	-1.2	
	Tools, furniture and fixtures	15.8	16.8	-0.9	
	Land	30.1	29.1	1.0	
	Construction in progress	18.6	13.9	4.7	
	Other	1.3	1.8	-0.4	
Intangible fixed assets		62.7	58.3	4.3	
	Goodwill	22.1	26.3	-4.2	- Goodwill (-4.2)
	Other	40.6	31.9	8.6	Decrease due to amortization of goodwill associated with Agensys.
Investments and other assets		128.3	144.9	-16.6	- Other(+8.6) Acquisition of sales right and patent, etc.
	Investment securities	70.7	89.5	-18.7	
	Deferred tax assets	46.8	46.2	0.6	
	Other	10.7	9.2	1.4	
	Allowance for doubtful receivables	-0.0	-0.0	0.0	

Billion yen

	31-Mar-10	31-Mar-09		
	Amount	Amount	Change	Comments
Liabilities and Net assets	1,364.1	1,348.4	15.7	
Liabilities	310.2	318.2	-7.9	
Current liabilities	277.1	283.5	-6.3	
Trade notes and accounts payable	84.0	89.7	-5.7	
Other accounts payable	93.9	91.7	2.1	
Accrued expenses	62.3	52.1	10.1	
Accrued income taxes	21.2	39.6	-18.4	
Accrued consumption tax	2.5	0.4	2.1	
Deferred tax liabilities	0.0	0.8	-0.8	
Accrued bonus for directors	0.0	0.1	0.0	
Allowance for sales rebates	3.6	2.7	0.9	
Other	9.3	6.0	3.2	
Long-term liabilities	33.0	34.6	-1.5	
Accrued retirement benefits for employees	17.6	15.0	2.6	
Accrued retirement benefits for directors	0.0	0.0	0.0	
Other	15.4	19.6	-4.2	
Net assets	1,053.9	1,030.2	23.7	
Common stock	103.0	103.0	-	- Retained earnings (-62.2)
Capital surplus	176.8	176.8	-	Net income (+122.2), Dividend of surplus (-56.4)
Retained earnings	895.1	957.3	-62.2	Cancellation of treasury stock (-128.0)
Treasury stock	-54.1	-155.2	101.1	-Treasury stock (+101.1)
Unrealized holding gains on securities	14.1	10.0	4.1	Cancellation of treasury stock (+128.0)
Translation adjustments	-82.5	-62.9	-19.6	Acquisition of treasury stock (-26.9)
Stock subscription rights	1.2	0.8	0.3	
Minority interests	0.3	0.3	0.0	